(Arylpiperazinyl)cyclohexylsufonamides: Discovery of α1a/1d-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS)

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 12, 2007, Pages 3292-3297

  Chiu, George ^a   Li, Shengjian ^a   Connolly, Peter J ^a   Pulito, Virginia ^a   Liu, Jingchun ^a   Middleton, Steven A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

1 Adrenergic receptors; 1a 1d Subtype selective antagonist; (Arylpiperazinyl)cyclohexylsulfonamides; BPH LUTS

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; DOPAMINE RECEPTOR; PIPERAZINE DERIVATIVE; SULFONAMIDE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; CARDIOVASCULAR DISEASE; DRUG ACTIVITY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LOWER URINARY TRACT SYMPTOM; MOLECULAR CLONING; NONHUMAN; PROSTATE HYPERTROPHY;

ADRENERGIC ALPHA-ANTAGONISTS; BINDING SITES; CLONING, MOLECULAR; HUMANS; LIGANDS; MALE; MODELS, CHEMICAL; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, DOPAMINE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; UROLOGIC DISEASES;

EID: 34249299761     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.04.008     Document Type: Article

References (26)

1. Shapiro E., and Lepor H. Urol. Clin. North Am. 22 (1995) 285
2. Berry S.J., Coffey D.S., Walsh P.C., and Ewing L.L. J. Urol. 132 (1984) 474
3. Lepor H., Meretyk S., and Knapp-Maloney G. J. Urol. 147 (1992) 1554
4. Caine M. J. Urol. 136 (1986) 1
5. Bruno J.F., Whittaker J., Song J., and Berelowitz M. Biochem. Biophys. Res. Commun. 179 (1991) 1485
6. Ramarao C.S., Kincade Denker J.M., Perez D.M., Galvin R.J., Riek R.P., and Graham R.M. J. Biol. Chem. 267 (1992) 21936
7. Hirasawa A., Horie K., Tanaka T., Takagaki K., Murai M., Yano J., and Tsujimoto G. Biochem. Biophys. Res. Commun. 195 (1993) 902
8. Forray C., Bard J.A., Wetzel J., Chiu G., Shapiro E., Tang R., LePor H., Hartig P.R., Weinshank R.L., Branchek T.A., and Gluchowski C. Mol. Pharmacol. 45 (1994) 703
9. Wetzel J.M., Miao S.W., Forray C., Borden L.A., Branchek T.A., and Gluchowski C. J. Med. Chem. 38 (1995) 1579
10. Wong W.C., Chiu G., Wetzel J.M., et al. J. Med. Chem. 41 (1998) 2643
11. Lagu B., Tian D., Chiu G., Nagarathram D., Fang J., Shen Q., Forray C., Ransom R.W., Chang R.S.L., Vyas K.P., Zhang K., and Gluchowski C. Bioorg. Med. Chem. Lett. 10 (2000) 175
12. Blue, D. R., Jr.; Grino, P. B.; Jung, D. T.; et al. In Proceedings of the Fifth International Consultation on BPH; June 25, 2000 [abstract].
13. Ilampel C., Dolber P.C., Smith M.P., et al. J. Urol. 167 (2002) 1513
14. Gu B., Reiter J.P., Schwinn D.A., et al. J. Urol. 172 (2004) 758
15. Smith M.S., Scharnbra U.M., Wilson K.H., Page S.O., and Schwinn D.A. Brain. Res. Mol. Brain Res. 63 (1999) 254
16. Cavalli A., Lattion A.L., Hummler E., et al. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 11589
17. Schwinn D.A., Price D.T., and Narayan P. Mayo Clin. Proc. 79 11 (2004) 1423
18. Roehrborn C.G., and Schwinn D. J. Urol. 171 (2004) 1029
19. Sarma P.K.S., Tiwari A., and Pal A. Expert Opin. Ther. Pat. 15 10 (2005) 1333
20. Daniels D.V., Gever J.R., Jasper J.R., Kava M.S., et al. Eur. J. Pharmacol. 370 (1999) 337
21. Lowe F.C. Clin. Ther. 26 (2004) 1701
22. Li S., Chiu G., Pulito V.L., Liu J., Connolly P.J., and Middleton S.A. Bioorg. Med. Chem. Lett. 17 6 (2007) 1646
23. Unpublished results.
24. f value is the trans isomer. This has been determined by 2-D NMR and confirmed by X-ray structure determination.
25. Genin M.J., Poel T.J., Yagi Y., Biles C., Althaus I., Keiser B.J., et al. J. Med. Chem. 39 (1996) 5267
26. 3) 1.20 (m, 4H), 1.33 (d, J = 6.1 Hz, 6H), 1.95 (bd, 2H), 2.05 (bd, 2H), 2.23 (m, 1H), 2.70 (m, 4H), 3.03 (m, 1H), 3.10 (br s, 4H), 3.95 (d, J = 7.1 Hz, NH, 1H), 4.23 (s, 2H), 4.56 (m, 1H), 6.8-7.5 (m, 9H). MS: 472 (M+1).